基本信息
views: 79
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Major Research Interests
Overview
Tumor cells utilize a very diverse array of mechanisms to proliferate uncontrolled and metastasize. Irrespective of the underlying cause of a tumor, essentially all tumor-specific changes ultimately converge in the altered “expression” of genes in the cell. The goal of our work is to understand the molecular processes by which tumor-specific changes in gene activity lead to tumorigenesis and tumor progression. More importantly, we aim to utilize this information to identify better and more efficient therapies for various gastrointestinal tumors.
Targeting epigenetics for anti-cancer therapy
Since essentially all tumor-specific changes that occur during the formation and metastasis of cancer ultimately converge on the genetic material, it makes the processes which control gene activity ideal anti-cancer targets. In fact, researchers worldwide, as well as numerous pharmaceutical companies, have made significant progress in identifying new approaches to target “epigenetic” processes in cancer. Numerous clinical studies are ongoing which will help to determine which types of cancer may respond best to these therapies.
“Bromodomain” proteins in gastrointestinal cancers
The Johnsen group has been studying a specific group of “epigenetic” regulators called “bromodomain” proteins. These proteins essentially function as the “middle man” which convert different signaling processes into changes in the ability of a gene to be in an “on” or “off” state. Importantly, these proteins can be specifically targeted by small molecule drugs, many of which are in early clinical trials for different types of cancer. We are currently examining the molecular mechanisms by which bromodomain proteins work in cancer as well as deciphering the characteristics of individual tumors, which determine whether they will respond to these treatments. In this way, we hope to uncover new approaches to be able to identify specific therapeutic approaches for treating individual patients based on the molecular makeup of their tumors, an approach frequently referred to as “precision oncology”.
Overview
Tumor cells utilize a very diverse array of mechanisms to proliferate uncontrolled and metastasize. Irrespective of the underlying cause of a tumor, essentially all tumor-specific changes ultimately converge in the altered “expression” of genes in the cell. The goal of our work is to understand the molecular processes by which tumor-specific changes in gene activity lead to tumorigenesis and tumor progression. More importantly, we aim to utilize this information to identify better and more efficient therapies for various gastrointestinal tumors.
Targeting epigenetics for anti-cancer therapy
Since essentially all tumor-specific changes that occur during the formation and metastasis of cancer ultimately converge on the genetic material, it makes the processes which control gene activity ideal anti-cancer targets. In fact, researchers worldwide, as well as numerous pharmaceutical companies, have made significant progress in identifying new approaches to target “epigenetic” processes in cancer. Numerous clinical studies are ongoing which will help to determine which types of cancer may respond best to these therapies.
“Bromodomain” proteins in gastrointestinal cancers
The Johnsen group has been studying a specific group of “epigenetic” regulators called “bromodomain” proteins. These proteins essentially function as the “middle man” which convert different signaling processes into changes in the ability of a gene to be in an “on” or “off” state. Importantly, these proteins can be specifically targeted by small molecule drugs, many of which are in early clinical trials for different types of cancer. We are currently examining the molecular mechanisms by which bromodomain proteins work in cancer as well as deciphering the characteristics of individual tumors, which determine whether they will respond to these treatments. In this way, we hope to uncover new approaches to be able to identify specific therapeutic approaches for treating individual patients based on the molecular makeup of their tumors, an approach frequently referred to as “precision oncology”.
Research Interests
Papers共 194 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Thomas L Ekstrom,Sajjad Hussain,Tibor Bedekovics,Asma Ali,Lucia Paolini, Hina Mahmood, Raya M Rosok,Jan Koster,Steven A Johnsen,Paul J Galardy
Molecular cancer research : MCR (2024)
Jannis Stadager, Chiara Bernardini, Laura Hartmann, Henrik May, Jessica Wiepcke, Monika Kuban,Zeynab Najafova,Steven A. Johnsen,Stefan Legewie,Franziska R. Traube,Julian Jude,Philipp Rathert
crossref(2024)
Evangelos Prokakis, Husam Bamahmoud, Shaishavi Jansari, Lena Fritsche, Alexander Dietz,Angela Boshnakovska,Peter Rehling,Steven A. Johnsen,Julia Gallwas,Florian Wegwitz
Cell Communication and Signalingno. 1 (2024): 1-17
Marie C. Hasselluhn,Denise Schloesser,Lennart Versemann,Geske E. Schmidt, Maria Ulisse, Joana Oschwald,Zhe Zhang,Feda Hamdan, Harry Xiao,Waltraut Kopp,Jessica Spitalieri,Christin Kellner,
Gastroenterologyno. 2 (2024): 298-+
Clinical Epigeneticsno. 1 (2024): 1-22
Gastroenterologyno. 4 (2024): 631-644.e17
crossref(2023)
Pancreatology (2023): e1-e1
crossref(2023)
Load More
Author Statistics
#Papers: 193
#Citation: 5869
H-Index: 43
G-Index: 74
Sociability: 7
Diversity: 3
Activity: 71
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn